Sequenom has appointed William Welch to senior vice president of diagnostics. He will be responsible for all commercial aspects of the company's diagnostics business and will report to Harry Hixson Jr., Sequenom's chairman and CEO.
Welch has more than 18 years' leadership experience in medical devices and biotechnology companies, most recently serving as the senior vice president and chief operating officer of Monogram Biosciences. Prior to Monogram, he was the vice president of sales and marketing at La Jolla Pharmaceuticals and vice president of global marketing at Dade Behring Microscan. He began his career in the healthcare industry at Abbott Laboratories.
Genomic Health has announced changes to its management.
Dean Schorno has been appointed chief financial officer, replacing G. Bradley Cole, who will continue to hold positions as the company's chief operating officer and secretary.
Schorno, who joined the company in 2001, has served as the company's senior vice president of finance since February 2010, and prior to that he held positions as the vice president of finance, vice president of operations, and he also led the company's finance group as a director and senior director.
Cole has held positions at Genomic Health since 2004. Prior to that, he served in various positions at the medical device company Guidant.
Genome British Columbia has appointed Brad Popovich as chief scientific officer. Popovich will promote the organization's scientific strategy, focusing on the science of genomics, proteomics, and bioinformatics. Popovich has more than 20 years of science and business experience, including his most recent position as president and CEO of Sirius Genomics, a private biotech company based in Vancouver.
Previously, Popovich headed the molecular diagnostics laboratory at Oregon Health Sciences University, and became the first executive director of the genetic services laboratory at OSHU. He also serves on the boards of Sirius Genomics, the Centre for Drug Research and Development Ventures, and Genetic Information Management Systems. He holds an MS in genetic counseling from Sarah Lawrence College, and an MS in biochemical genetics and PhD in molecular genetics from McGill University.
Saladax Biomedical has appointed Edward Erickson as president and CEO. Prior to joining Saladax, Erickson served as president and CEO of BioNanomatrix, and he was also previously the chairman, president, and CEO of Cellatope Corporation, a private company developing diagnostic products for autoimmune diseases.
Erickson has also served in leadership roles at medical products companies Immunicon, DepoTech, and Cholestech. He is currently a director of BioNanomatrix, Metabolon, and MDxHealth. He holds an MBA from the Harvard Graduate School of Business Administration, and an MS and BS from the Illinois Institute of Technology. He also did military service as an officer in the US Navy's nuclear submarine force.